Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) Interest Coverage: N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$27.40
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Hanx Biopharmaceuticals (Wuhan) Co's Operating Income for the six months ended in Dec. 2025 was HK$0.00 Mil. Hanx Biopharmaceuticals (Wuhan) Co's Interest Expense for the six months ended in Dec. 2025 was HK$0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage or its related term are showing as below:


HKSE:03378's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 105.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hanx Biopharmaceuticals (Wuhan) Co  (HKSE:03378) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage Related Terms

Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
Interest Coverage
0.00 0.00 0.00

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25 Jun26
Interest Coverage N/A N/A N/A 0.00

HKSE:03378 vs VRTX, REGN, MRNA: Interest Coverage Comparison

For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage falls into.


HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Hanx Biopharmaceuticals (Wuhan) Co's Interest Expense was HK$-12.83 Mil. Its Operating Income was HK$-165.65 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$24.69 Mil.

Hanx Biopharmaceuticals (Wuhan) Co did not have earnings to cover the interest expense.

Hanx Biopharmaceuticals (Wuhan) Co's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Hanx Biopharmaceuticals (Wuhan) Co's Interest Expense was HK$0.00 Mil. Its Operating Income was HK$0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$24.69 Mil.

GuruFocus does not calculate Hanx Biopharmaceuticals (Wuhan) Co's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.40
Price